More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development
You may also be interested in...
Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference
CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear
Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference
CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear
Aussie Health Chief Vows To End Delay In Doctor PBS Prescriptions
Australia's health minister says the government is taking steps to ease some of the delays in physician ability to prescribe covered drugs